A Clinical Trial Evaluating a Total Disc Replacement in Patients With Cervical Disc Disease

Cervical Disc Disease Clinical Trial

— CerPass  

Official title:

A Prospective Observational Study Evaluating the Performance of the CerPass® Total Disc Replacement in Patients With Single-Level Cervical Disc Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01433367
• Other study ID #: NUVA-CP-0904
• Status: Terminated
• Phase: N/A
• First received: June 10, 2011
• Last updated: April 17, 2015
• Start date: May 2010
• Est. completion date: December 2013

Study information

• Verified date: April 2015
• Source: NuVasive
• Contact: n/a
• Is FDA regulated: No
• Health authority: Venezuela: Ethics Committee
• Study type: Observational

Clinical Trial Summary

This study will be a non-randomized trial consisting of patients with single level (C3 to C7) symptomatic cervical disc disease who have not previously received fusion surgery at the same level, and have failed to improve with conservative treatment for at least 6 weeks prior to enrollment, or who present with progressive neurological symptoms or signs in the face of conservative treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

The criteria for inclusion into the proposed clinical study are as follows:

1. Age: 18-60 years of age (inclusive and skeletally mature);

2. A diagnosis of symptomatic cervical disc disease, defined as image-confirmed pathology: herniated disc, spondylosis, and/or loss of disc height. Spondylosis is defined as image-confirmed disc desiccation, loss of disc height, bridging osteophytes, and/or uncovertebral arthrosis. Loss of disc height is specified as a measurement of at least 25 degrees less than an adjacent nonsymptomatic level, but with a minimum of 1mm height remaining;

3. Functional neurological deficit (i.e., exhibits at least one sign associated with cervical level to be treated, including abnormal reflex, decreased motor strength, abnormal dermatome sensitivity, or pain in a dermatomal distribution);

4. Symptomatic level is C3-4, C4-5, C5-6 or C6-7 (one level);

5. Preoperative Neck Disability Index (NDI) greater than 30 points (considered moderate disability; Vernon 1991);

6. Unresponsive to conservative treatment for more than 6 weeks, and/or exhibits progressive symptoms and/or signs of nerve root and/or spinal cord compression in the face of conservative treatment;

7. Not pregnant, nor interested in becoming pregnant within the follow-up period of the study;

8. Willing and able to comply with the requirements defined in the protocol for the duration of the study;

9. Signed and dated Informed Consent.

Exclusion Criteria:

Patients with the following characteristics will not be eligible for entry into the proposed study:

1. Prior cervical fusion, prior laminectomy (prior cervical laminotomy that has not violated the facets need not be excluded), and/or prior cervical facetectomy at the operative level;

2. Requiring surgical treatment that would leave the patient with a postoperative deficiency of the posterior elements;

3. Signal changes in the cord on preoperative T2-weighted MRI and/or clinically significant myelopathy which would be described as gait disturbance, loss of manual dexterity, or bowel or bladder incontinence/retention.

4. Radiographic signs of significant instability at operative level (greater than 3mm translation, greater than 11 degree rotation different from adjacent level);

5. Bridging osteophytes or motion < 3 degrees;

6. Radiographic confirmation of significant facet joint disease or degeneration;

7. Chronic neck or arm pain of unknown etiology;

8. Cervical fracture, anatomic anomaly, or deformity (e.g. ankylosing spondylitis, scoliosis) at the levels to which the prosthesis will be attached;

9. Severe spondylolisthesis (greater than grade 1);

10. Endocrine disorders or connective tissue diseases;

11. Rheumatoid arthritis or other autoimmune disease;

12. Progressive neuromuscular disease, e.g., muscular dystrophy, multiple sclerosis;

13. Chronic steroid users;

14. Taking any medications or drugs in doses that are known to potentially interfere with the bone metabolism or soft tissue healing, which may include (but is not limited to) the following: inhaled glucocorticoids for asthma, corticosteroids, thyroid hormones, blood thinners (heparin, warfarin), gonadotropin-releasing hormone agonists for prostate cancer treatment, contraceptive medroxyprogesterone, lithium for bi-polar disorder treatment, anticonvulsants, aluminum-containing antacids, tetracycline;

15. Osteoporosis to a degree that spinal instrumentation would be contraindicated (DEXA T-score less than or equal to -2.5; DEXA necessary only if patient exhibits risk factors for low bone mass as quantified in DEXA screening questionnaire);

16. Diabetes mellitus requiring insulin management;

17. Presence of metastases or active spinal tumor malignancy;

18. Body Mass Index (BMI) > 40;

19. Active local or systemic infection, including AIDS, hepatitis;

20. Having been enrolled in another investigational device study within the last 90 days;

21. Having had another cervical device implanted that would interfere with the surgical approach, study or control device, or follow-up evaluations;

22. Demonstrates 3 or more signs of nonorganic behavior, such as Waddell's signs;

23. History of substance abuse;

24. Involved in spinal litigation;

25. Mentally incompetent;

26. Incarcerated.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cervical Disc Disease
• Spinal Diseases

Intervention

Device:
• CerPass® Total Disc Replacement
Single level cervical disc disease

Locations

Country	Name	City	State
Mexico	Hospital Del Prado	Tijuana	Baja California

Sponsors (1)

Lead Sponsor	Collaborator
NuVasive

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoints will be individual patient success at 24 months.	Success is defined as: Improvement in the Neck Disability Index (NDI) by = 15 points at 24 months compared to Baseline; No device failures requiring revision, re-operation (including supplemental fixation), or removal from the patient; Maintenance or improvement of neurologic status (based on sensory, motor, and reflex assessment scores and observational gait analysis).	24 months	Yes
Secondary	Range of motion (ROM)	Range of Motion (ROM) defined as more than 3 degrees total flexion / extension. If the ROM is less than or equal to 3º the patient will be defined as having "non-motion."	24 months	No
Secondary	SF-36	SF-36 improvement of 15% at 24 months compared to Baseline	24-months	No
Secondary	VAS analog pain scale (VAS)	Visual analog pain scale (VAS) improvement of 20 mm at 24 months compared to Baseline	24-months	No
Secondary	Disc height improvement	Disc height from the lateral radiograph showing maintenance or improvement from baseline at 24 months.	24-months	No